These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 36059987)

  • 1. Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?
    Zhao F; Cheng Z; Piao J; Cui R; Li B
    Front Pharmacol; 2022; 13():947785. PubMed ID: 36059987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.
    Kiss B; Laszlovszky I; Krámos B; Visegrády A; Bobok A; Lévay G; Lendvai B; Román V
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33466844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease.
    Napier TC; Kirby A; Persons AL
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Aug; 102():109942. PubMed ID: 32272129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the role of heteroreceptor complexes in the central nervous system.
    Fuxe K; Borroto-Escuela D; Fisone G; Agnati LF; Tanganelli S
    Curr Protein Pept Sci; 2014; 15(7):647. PubMed ID: 25256022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic Modulation of Synaptic Plasticity, Its Role in Neuropsychiatric Disorders, and Its Computational Modeling.
    Madadi Asl M; Vahabie AH; Valizadeh A
    Basic Clin Neurosci; 2019; 10(1):1-12. PubMed ID: 31031889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors.
    Beaulieu JM; Del'guidice T; Sotnikova TD; Lemasson M; Gainetdinov RR
    Front Mol Neurosci; 2011; 4():38. PubMed ID: 22065948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine receptors - IUPHAR Review 13.
    Beaulieu JM; Espinoza S; Gainetdinov RR
    Br J Pharmacol; 2015 Jan; 172(1):1-23. PubMed ID: 25671228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of dopamine in reward and pleasure behaviour--review of data from preclinical research.
    Bressan RA; Crippa JA
    Acta Psychiatr Scand Suppl; 2005; (427):14-21. PubMed ID: 15877719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.
    Haleem DJ
    Behav Pharmacol; 2015 Feb; 26(1-2):45-58. PubMed ID: 25503261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression.
    Leggio GM; Salomone S; Bucolo C; Platania C; Micale V; Caraci F; Drago F
    Eur J Pharmacol; 2013 Nov; 719(1-3):25-33. PubMed ID: 23872400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated pathophysiology of schizophrenia, major depression, and bipolar disorder as monoamine axon disorder.
    Nakamura S
    Front Biosci (Schol Ed); 2022 Jan; 14(1):4. PubMed ID: 35320915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polypharmacology of dopamine receptor ligands.
    Butini S; Nikolic K; Kassel S; Brückmann H; Filipic S; Agbaba D; Gemma S; Brogi S; Brindisi M; Campiani G; Stark H
    Prog Neurobiol; 2016 Jul; 142():68-103. PubMed ID: 27234980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Delpont B; Lhommée E; Klinger H; Schmitt E; Bichon A; Fraix V; Castrioto A; Quesada JL; Pélissier P; Kistner A; Carnicella S; Lüscher C; Broussolle E; Pollak P; Thobois S; Krack P
    Mov Disord; 2017 Nov; 32(11):1566-1573. PubMed ID: 28737225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormalities of Dopamine D
    Prieto GA
    J Cent Nerv Syst Dis; 2017; 9():1179573517726335. PubMed ID: 28855798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depression and impulse control disorders in Parkinson's disease: two sides of the same coin?
    Vriend C; Pattij T; van der Werf YD; Voorn P; Booij J; Rutten S; Berendse HW; van den Heuvel OA
    Neurosci Biobehav Rev; 2014 Jan; 38():60-71. PubMed ID: 24239733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anatomy of co-morbid neuropsychiatric disorders based on cortico-limbic synaptic interactions.
    Totterdell S
    Neurotox Res; 2006 Oct; 10(2):65-85. PubMed ID: 17062369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of monoaminergic targets in the antidepressant- and anxiolytic-like effects of the synthetic alkamide riparin IV: Elucidation of further mechanisms through pharmacological, neurochemistry and computational approaches.
    Sartori DP; Oliveira NF; Valentim JT; Silva DMA; Mallman ASV; Oliveira ICM; Chaves RC; Capibaribe VC; Carvalho AMR; Rebouças MO; Macedo DS; Chaves Filho AJM; Fonteles MMF; Gutierrez SJC; Barbosa-Filho JM; Mottin M; Andrade CH; Sousa FCF
    Behav Brain Res; 2020 Apr; 383():112487. PubMed ID: 31987932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective.
    Goto Y; Grace AA
    Int Rev Neurobiol; 2007; 78():41-68. PubMed ID: 17349857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex Differences in Dopamine Receptors and Relevance to Neuropsychiatric Disorders.
    Williams OOF; Coppolino M; George SR; Perreault ML
    Brain Sci; 2021 Sep; 11(9):. PubMed ID: 34573220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia.
    Abramsky O; Litvin Y
    Perspect Biol Med; 1978; 22(1):104-14. PubMed ID: 733451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.